ANKTIVA, developed by ImmunityBio, has received FDA approval for use in combination with BCG (Bacillus Calmette-Guérin) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This drug leverages the immune system, particularly by stimulating natural killer (NK) cells and T cells, to fight cancer, offering a promising new treatment option for patients who previously faced invasive surgery
- HCW Investor Conference Presentation (Question at 23:00)
- Recap
- Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint inhibitors such as KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab)
- ANKTIVA plus KEYTRUDA or OPDIVO rescued T cell activity in these patients who progressed on the same checkpoint inhibitor with overall survival of 57% at 12 months
- Long-term survival was independent of PDL1 tumor status and independent of 2nd or 3rd line of therapy
- The data continues to validate the mechanism of action of ANKTIVA in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in patients with advanced cancers
- Data supports global launch of Phase 3 randomized control of ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1st and 2nd line NSCLC (ResQ301 and ResQ302) versus standard of care
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
- For further reading
Leave a Reply